Angiozyme: RZYM submitted an IND to the FDA to begin Phase I testing

Ribozyme Pharmaceuticals Inc. (RZYM), Boulder, Colo. Product: Angiozyme inhibitor of vascular endothelial growth factor receptor (VEGFr) Indication: Treat cancer Status: RZYM submitted an IND to the ...